Boudicca Dx. is a global precision medicine testing accelerator with a best-in-class team of consultants & strategic alliance partners that is immediately deployed as a unified team to help clients become first-in-class and deliver precision therapies & high-value, high-quality precision medicine testing to patients faster. Boudicca Dx. supports precision medicine testing development (LDTs & IVDs) from concept through commercial launch.
Boudicca Dx. has supported 56 Biopharma (8 acquisitions & 3 IPOs), 36 Dx (LDT & IVD) Developers (2 acquisitions, out-licensing of 3 tests, & 5 breakthrough-designated devices), multiple consulting & investment firms.
Boudicca Dx. has supported clients with both non-oncology (21 clients) & oncology (71 clients) precision medicine programs. Oncology experience includes both hematological malignancies & solid tumors. Non-oncology experience includes Alpha-1 antitrypsin deficiency (AATD)-lung disease, Alcohol Use Disorder, Alzheimer’s Disease, autoimmune disease, arrhythmogenic cardiomyopathy, cardiac Friedreich’s Ataxia, chronic respiratory disorders, DiGeorge syndrome/22q11.2 deletion syndrome, GRN-related frontotemporal lobar degeneration, Hemophilia A, infectious diseases, Inflammatory Bowel Disease, Fabry Disease, Fibrosis, Parkinson’s Disease, Preeclampsia, Septic Shock, Transthyretin (ATTR) Amyloidosis, and X-linked chronic granulomatous disease.
Boudicca Dx. has supported clinical biomarker and companion diagnostic (CDx) co-development for antibody-drug conjugates, allogeneic CAR T cell products, autologous T cell therapies, bispecific T-cell engagers (BiTEs), gene therapies (Adeno-associated virus [AAV] vectors, CRISPR/CAS9 lipid nanoparticles (LNPs), immunotherapies, monoclonal antibodies, small molecule inhibitors, RNA interference-based therapies, and T cell receptor natural killer cell therapies.